🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

56+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 56 recruiting trials for “vaginal-carcinoma

EARLY_Phase 1RecruitingNCT06586658

Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells

👨‍⚕️ Shancheng Ren, MD,PhD, Shanghai Changzheng Hospital📍 1 site📅 Started Sep 2024View details ↗
EARLY_Phase 1RecruitingNCT06318871

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

👨‍⚕️ Wenxin Xu, MD, Dana-Farber Cancer Institute📍 2 sites📅 Started Aug 2024View details ↗
RecruitingNCT06720532

Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial

🏥 Hannah Schaefer📍 1 site📅 Started Aug 2024View details ↗
NARecruitingNCT06519760

68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma

👨‍⚕️ Kan Gong, Peking University First Hospital📍 1 site📅 Started Jul 2024View details ↗
Phase 1RecruitingNCT06399419

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

👨‍⚕️ Alex Chehrazi-Raffle, MD, City of Hope Medical Center📍 1 site📅 Started Jun 2024View details ↗
RecruitingNCT06548867

Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

👨‍⚕️ Carmine Pinto, MD, AUSL/IRCCS of Reggio Emilia📍 1 site📅 Started May 2024View details ↗
Phase 2RecruitingNCT06265285

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

👨‍⚕️ Roxana S. Dronca, M.D., Mayo Clinic📍 1 site📅 Started Apr 2024View details ↗
Phase 1RecruitingNCT06259552

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

👨‍⚕️ Guidong Zhu, SparX Biotech📍 4 sites📅 Started Mar 2024View details ↗
NARecruitingNCT05410509

"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

👨‍⚕️ Andrew Gunn, MD, University of Alabama at Birmingham📍 4 sites📅 Started Jan 2024View details ↗
Phase 2RecruitingNCT05931393

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

👨‍⚕️ Tian Zhang, MD, University of Texas Southwestern Medical Center📍 1 site📅 Started Dec 2023View details ↗
Phase 1RecruitingNCT06010875

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

👨‍⚕️ Fei Li, M.D, The First Affiliated Hospital of Nanchang University📍 1 site📅 Started Nov 2023View details ↗
Phase 1, PHASE2RecruitingNCT05808608

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

👨‍⚕️ Hao Zeng, Professor, West China Hospital📍 1 site📅 Started Nov 2023View details ↗
NARecruitingNCT06101290

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

👨‍⚕️ Mamta Parikh, MD, MS, University of California, Davis📍 1 site📅 Started Oct 2023View details ↗
RecruitingNCT06391879

Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma

👨‍⚕️ Kan Gong, Peking University First Hospital📍 1 site📅 Started Sep 2023View details ↗
RecruitingNCT06076538

PET/MR for Characterization of Renal Masses (RMs)

👨‍⚕️ Ivan Pedrosa, MD, PhD, University of Texas Southwestern Medical Center📍 1 site📅 Started Aug 2023View details ↗
Phase 1RecruitingNCT05868174

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

🏥 Telix Pharmaceuticals (Innovations) Pty Limited📍 5 sites📅 Started May 2023View details ↗
Phase 3RecruitingNCT05738694

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

👨‍⚕️ Fangjian Zhou, Professor, Director of Dept. of Urology, Sun Yat-sen University Cancer Center📍 8 sites📅 Started Apr 2023View details ↗
RecruitingNCT05184790

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

👨‍⚕️ Paul Keall, Professor📍 4 sites📅 Started Feb 2023View details ↗
Phase 2RecruitingNCT05361720

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

👨‍⚕️ Brian I Rini, MD, Vanderbilt University/Ingram Cancer Center📍 6 sites📅 Started Dec 2022View details ↗
Phase 1RecruitingNCT05536141

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

👨‍⚕️ Medical Director, Arcus Biosciences📍 29 sites📅 Started Oct 2022View details ↗
← PreviousPage 2 of 3Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →